Search Result

Results for "

JAK1 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (1) Apoptosis (27) Autophagy (8) Bacterial (3) Bcl-2 Family (1) Btk (1) Calcium Channel (1) Cathepsin (1) CXCR (1) Drug Metabolite (1) FLT3 (7) Fungal (3) G Protein-coupled Receptor Kinase (GRK) (1) GSK-3 (1) HDAC (1) HIV (2) IAP (1) IFNAR (3) Influenza Virus (3) Interleukin Related (6) Isotope-Labeled Compounds (6) JAK (145) Mitophagy (4) mTOR (1) NF-κB (1) p38 MAPK (2) PKC (1) Polo-like Kinase (PLK) (1) PPAR (1) Protease Activated Receptor (PAR) (1) Pyroptosis (1) Ras (1) Reactive Oxygen Species (1) SOD (1) Src (1) STAT (17) STING (1) Survivin (1) Syk (4) TNF Receptor (5) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (78) Cardiovascular Disease (3) Infection (5) Inflammation/Immunology (75) Metabolic Disease (1)

By Targets:

Akt (1)

AMPK (1)

Apoptosis (27)

Autophagy (8)

Bacterial (3)

Bcl-2 Family (1)

Btk (1)

Calcium Channel (1)

Cathepsin (1)

CXCR (1)

Drug Metabolite (1)

FLT3 (7)

Fungal (3)

G Protein-coupled Receptor Kinase (GRK) (1)

GSK-3 (1)

HDAC (1)

HIV (2)

IAP (1)

IFNAR (3)

Influenza Virus (3)

Interleukin Related (6)

Isotope-Labeled Compounds (6)

JAK (145)

Mitophagy (4)

mTOR (1)

NF-κB (1)

p38 MAPK (2)

PKC (1)

Polo-like Kinase (PLK) (1)

PPAR (1)

Protease Activated Receptor (PAR) (1)

Pyroptosis (1)

Ras (1)

Reactive Oxygen Species (1)

SOD (1)

Src (1)

STAT (17)

STING (1)

Survivin (1)

Syk (4)

TNF Receptor (5)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (78)

Cardiovascular Disease (3)

Infection (5)

Inflammation/Immunology (75)

Metabolic Disease (1)

148

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-161015

JAK1-IN-13	JAK	Inflammation/Immunology
JAK1-IN-13 (compound 36b) is an orally active, potent and highly selective inhibitor of *JAK1* with an IC₅₀ of 0.044 nM. JAK1-IN-13 significantly decreases STAT3 phosphorylation .

HY-153568

JAK1-IN-11	JAK	Cancer
JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC₅₀s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2 .

HY-116505

JAK1-IN-4	JAK	Cancer
JAK1-IN-4 is a potent and selective *JAK1* inhibitor, with IC₅₀s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC₅₀, 227 nM) .

HY-149296

JAK1-IN-12	JAK	Inflammation/Immunology
JAK1-IN-12 is a selective inhibitor of *JAK1, with IC₅₀* of 0.0246 μM. And IC₅₀s of 0.423 μM, 0.410 μM and 1.12 μM for JAK2, JAK3 and TYK2. JAK1-IN-12 promotes hair growth in mice. JAK1-IN-12 can be used for research of immune and inflammatory diseases .

HY-161139

JAK1-IN-14	JAK	Inflammation/Immunology
JAK1-IN-14 (Compound 12a) is a potent and selective *JAK1* inhibitor. JAK1-IN-14 inhibits *JAK1* and JAK2 with an IC₅₀ value of 12.6 nM and 135 nM. JAK1-IN-14 suppresses hepatic fibrosis levels and can be used for the research of liver fibrosis and inflammatory diseases .

HY-144440

JAK1-IN-9	JAK	Cancer
JAK1-IN-9 (compound 23a) is a potent and selective *JAK1* inhibitor with an IC₅₀ of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more .

HY-138222

JANEX-1 hydrochloride WHI-P131 hydrochloride; JAK3 Inhibitor I hydrochloride	JAK	Cancer
JANEX-1 (WHI-P131) hydrochloride is a potent and specific JAK3 inhibitor (K_i=2.3 μM). JANEX-1 hydrochloride shows potent JAK3 inhibitory activity (IC₅₀=78 μM), does not inhibit *JAK1* and JAK2 .

HY-153566

JAK1-IN-10	JAK	Cancer
JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, is a potent and selective *JAK1* inhibitor .

HY-170977

JAK1/STAT3-IN-1	JAK STAT	Inflammation/Immunology
JAK1/STAT3-IN-1 (compound 4f) is an anti-AD (atopic dermatitis) agent by inhibiting *JAK1/STAT3* signaling pathway. JAK1/STAT3-IN-1 inhibits NO generation with an IC₅₀ of 2.17 μM. JAK1/STAT3-IN-1 improves the skin condition of AD-like mice, reduces inflammatory infiltration, inhibits the expressions of p-JAK1/JAK1 and p-STAT3/STAT3, and mitigates the excessive immune response on MC903 (Calcipotriol HY-10001)-induced AD-like mice .

HY-145336

JAK1/TYK2-IN-1	JAK	Cancer
JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and *JAK1* (IC₅₀ = 29 and 41 nM respectively).

HY-169242

JAK1-IN-16	JAK STAT Toll-like Receptor (TLR)	Cancer
JAK1-IN-16 (compound 4l) is an inhibitor of *JAK1/STAT3* and effectively downregulates TLR4 protein expression. .

HY-145588A

Povorcitinib phosphate INCB54707 phosphate	JAK TNF Receptor	Inflammation/Immunology
Povorcitinib (INCB54707) phosphate is a potent and selective *JAK1* inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib phosphate can be used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1) .

HY-139423

JAK1-IN-8	JAK	Inflammation/Immunology Cancer
JAK1-IN-8, a potent *JAK1* inhibitor (IC₅₀<500 nM), compound 28, extracted from patent WO2016119700A1 .

HY-168269

Tyk2-IN-20	JAK	Cancer
Tyk2-IN-20 (Example 289) is a potent Tyk2 inhibitor with an IC₅₀ of <5 nM. Tyk2-IN-20 als inhibits *JAK1, JAK2, and JAK3* with IIC₅₀ values of <100 nM. Tyk2-IN-20 can be used for the study of inflammatory diseases .

HY-143885

JAK1/TYK2-IN-3	JAK	Inflammation/Immunology
JAK1/TYK2-IN-3 is a potent, selective and orally active dual *TYK2/JAK1* inhibitor with IC₅₀ values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative to JAK2 (IC₅₀=140 nM) and JAK3 (IC₅₀=362 nM). JAK1/TYK2-IN-3 shows anti-inflammatory effect by regulating the expression of related *TYK2/JAK1*-regulated genes, as well as the formation of Th1, Th2, and Th17 cells .

HY-16997

Itacitinib 10+ Cited Publications INCB039110	JAK	Cancer
Itacitinib (INCB039110) is an orally active and selective inhibitor of *JAK1* with an IC₅₀ of 2 nM for human JAK1. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis .

HY-161019

JAK1/TYK2-IN-4	JAK	Inflammation/Immunology
JAK1/TYK2-IN-4 is a dual inhibitor of JAK and TYK2, with IC₅₀s of 39 nM and 21 nM, respectively. JAK1/TYK2-IN-4 has oral bioavailability .

HY-162248

JAK1/2-IN-1	JAK Interleukin Related	Inflammation/Immunology Cancer
JAK1/2-IN-1 is a potent *JAK1* and JAK2 inhibitor with IC₅₀ values of 0.4 nM and 8.1 nM, respectively. JAK1/2-IN-1 also inhibits IL-4 and IL-13 with IC₅₀s of 136.5 nM and 19.1 nM, respectively (WO2023244775A1; Example 33a) .

HY-112724A

Ivarmacitinib sulfate SHR0302 sulfate	JAK Apoptosis	Inflammation/Immunology Cancer
Ivarmacitinib (SHR0302) sulfate is a potent and orally active all members of the JAK family inhibitor, particularly *JAK1. The selectivity of Ivarmacitinib for JAK1* is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits *JAK1-STAT3* phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .

HY-112724

Ivarmacitinib SHR0302	JAK Apoptosis	Inflammation/Immunology Cancer
Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly *JAK1. The selectivity of Ivarmacitinib for JAK1* is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits *JAK1-STAT3* phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .

HY-18300S

Filgotinib-d4 GLPG0634-d₄	JAK	Cancer
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-13827

JAK-IN-1 1 Publications Verification	JAK	Inflammation/Immunology
JAK-IN-1 is a *JAK1/2/3* inhibitor with IC₅₀s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.

HY-112442

AZ-3	JAK	Cancer
AZ-3 is a potent and selective *JAK1* inhibitor with an IC₅₀ of 34 nM.

HY-139807

JAK-IN-14	JAK	Inflammation/Immunology
JAK-IN-14 is a potent and selective *JAK1* inhibitor, with an IC₅₀ of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16) .

HY-18300R

Filgotinib (Standard)	JAK	Cancer
Filgotinib (Standard) is the analytical standard of Filgotinib. This product is intended for research and analytical applications. Filgotinib (GLPG0634) is a selective and orally active *JAK1* inhibitor with IC₅₀ of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-152080

TUL01101	JAK	Inflammation/Immunology
TUL01101 is a potent, selective and orally active *JAK1* inhibitor, with an IC₅₀s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. TUL01101 can be used for the research of rheumatoid arthritis .

HY-139837

GDC-4379	JAK	Inflammation/Immunology
GDC-4379 is a *JAK1* inhibitor that can be used for the research of asthma .

HY-50859

Ruxolitinib sulfate INCB018424 sulfate	JAK Autophagy	Cancer
Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective *JAK1/2* inhibitor to enter the clinic with IC₅₀s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.

HY-13577

Oclacitinib 4 Publications Verification PF-03394197	JAK	Inflammation/Immunology
Oclacitinib is a novel JAK inhibitor. Oclacitinib is most potent at inhibiting *JAK1* (IC₅₀=10 nM).

HY-15315A

Baricitinib phosphate 50+ Cited Publications LY3009104 phosphate; INCB028050 phosphate	JAK	Inflammation/Immunology
Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable *JAK1/JAK2* inhibitor with IC₅₀ of 5.9 nM and 5.7 nM, respectively.

HY-50856

Ruxolitinib Maximum Cited Publications 162 Publications Verification INCB18424	JAK Autophagy Mitophagy Apoptosis	Cancer
Ruxolitinib (INCB18424) is an orally active and selective *JAK1/2* inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .

HY-107429

Abrocitinib 5+ Cited Publications PF-04965842	JAK	Inflammation/Immunology
Abrocitinib (PF-04965842) is a potent, orally active and selective *JAK1* inhibitor, with IC₅₀s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC₅₀, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease .

HY-16997A

Itacitinib adipate 10+ Cited Publications	JAK	Cancer
Itacitinib adipate is an orally bioavailable and selective *JAK1* inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.

HY-10963

Momelotinib mesylate CYT387 mesylate	JAK Autophagy	Cancer
Momelotinib mesylate (CYT387 mesylate) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀ of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.

HY-151385

VVD-118313	JAK STAT IFNAR Interleukin Related	Cancer
VVD-118313 (compound 5a) is a potent, selective *JAK1* inhibitor. VVD-118313 targets an isoform-restricted allosteric cysteine to block JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancer . VVD-118313 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13577A

Oclacitinib monomaleate 4 Publications Verification PF-03394197 monomaleate	JAK	Inflammation/Immunology
Oclacitinib maleate (PF-03394197 maleate) is a novel JAK inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting *JAK1* (IC₅₀=10 nM).

HY-126294

Londamocitinib AZD4604; JAK1-IN-7	JAK	Inflammation/Immunology
Londamocitinib (AZD4604) is a potent and selective *JAK1* inhibitor with IC₅₀ at 0.54 nM. Londamocitinib has anti-inflammatory activity .

HY-19569A

Upadacitinib tartrate tetrahydrate ABT-494 tartrate tetrahydrate	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research .

HY-19569

Upadacitinib 15+ Cited Publications ABT-494	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-10961

Momelotinib 10+ Cited Publications CYT387	JAK Autophagy Apoptosis	Cancer
Momelotinib (CYT387) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.

HY-13961

GLPG0634 analog	JAK	Cancer
GLPG0634 analog (Compoun 176) is a broad spectrum JAK inhibitor with IC₅₀ values of <100 nM against JAK1, JAK2 and JAK3 .

HY-151385A

(R,R)-VVD-118313	STAT Interleukin Related IFNAR JAK	Cancer
(R,R)-VVD-118313 is the isomer of VVD-118313 (HY-151385). VVD-118313 is a selective *JAK1* inhibitor and blocks JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancer . (R,R)-VVD-118313 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-162031

MMT3-72-M2	JAK	Metabolic Disease
MMT3-72-M2 is an MMT3-72 metabolite. MMT3-72-M2 is a selective *JAK1* inhibitor. MMT3-72-M2 inhibits JAK1, JAK2, TYK2, and JAK3 with IC₅₀ values of 10.8 nM, 26.3 nM, 91.6 nM, 328.7 nM, respectlly .

HY-50856R

Ruxolitinib (Standard)	JAK Autophagy Mitophagy Apoptosis	Cancer
Ruxolitinib (Standard) is the analytical standard of Ruxolitinib. This product is intended for research and analytical applications. Ruxolitinib (INCB18424) is a potent and selective *JAK1/2* inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .

HY-15315

Baricitinib 50+ Cited Publications LY3009104; INCB028050	JAK	Inflammation/Immunology
Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable *JAK1* and JAK2 inhibitor with IC₅₀s of 5.9 nM and 5.7 nM, respectively.

HY-100895

SAR-20347 1 Publications Verification	JAK	Cancer
SAR-20347 is an inhibitor of TYK2, *JAK1, JAK2* and JAK3 with IC₅₀s of 0.6, 23, 26 and 41 nM, respectively.

HY-10193A

(1R)-AZD-1480	JAK	Cancer
(1R)-AZD-1480 is the (1R) chiral isomer of AZD-1480, an ATP competitive *JAK1* and JAK2 inhibitor .

HY-10193

AZD-1480 10+ Cited Publications	JAK	Cancer
AZD-1480 is an ATP-competitive inhibitor of *JAK1* and JAK2 with IC₅₀s of 1.3 nM and <0.4 nM, respectively .

HY-107429R

Abrocitinib (Standard)	JAK	Inflammation/Immunology
Abrocitinib (Standard) is the analytical standard of Abrocitinib. This product is intended for research and analytical applications. Abrocitinib (PF-04965842) is a potent, orally active and selective *JAK1* inhibitor, with IC₅₀s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC₅₀, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease .

HY-163653

Zemprocitinib	JAK	Cancer
Zemprocitinib (Compound 1) is a Janus kinase (JAK) inhibitor. The IC₅₀ values for JAK1, JAK2 and TYK2 are 5.95, 141.3 and 119 nM, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6850

Calenduloside E 1 Publications Verification	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Other Diseases Aralia elata (Miq.) Seem. Plants Endogenous metabolite Disease Research Fields Araliaceae	Apoptosis Pyroptosis AMPK Bcl-2 Family JAK STAT Calcium Channel Interleukin Related TNF Receptor SOD Reactive Oxygen Species PPAR
Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated *JAK1-STAT3* pathways to reduce cellular inflammatory responses .

Cat. No.	Product Name	Chemical Structure

HY-50856S

Deuruxolitinib
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active *JAK1* and JAK2 inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata .

HY-15315S1

Baricitinib-d3
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-40354AS

Tofacitinib-d3 citrate
Tofacitinib-d₃ (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

HY-144031S

Tyk2-IN-8
Tyk2-IN-8 is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease[1].

HY-W727879

Upadacitinib-15N,d2

1 Publications Verification

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-50856S2

Ruxolitinib-d9
Ruxolitinib-d₉ (INCB18424-d₉) is deuterium labeled Ruxolitinib. Ruxolitinib (INCB18424) is an orally active and selective *JAK1/2* inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .

HY-15315S

Baricitinib-d5
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-169984S

Tyk2-IN-22-d3
Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22 (HY-168339). Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits Tyk2, *JAK1, and JAK3* with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation .

HY-10409S

Fedratinib-d9

Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks